643 related articles for article (PubMed ID: 15070917)
21. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
Aydin K; Cinar N; Aksoy DY; Bozdag G; Yildiz BO
Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
[TBL] [Abstract][Full Text] [Related]
22. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism.
Ibáñez L; Potau N; Ferrer A; Rodriguez-Hierro F; Marcos MV; De Zegher F
J Clin Endocrinol Metab; 2002 Dec; 87(12):5702-5. PubMed ID: 12466374
[TBL] [Abstract][Full Text] [Related]
23. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
24. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
Tfayli H; Ulnach JW; Lee S; Sutton-Tyrrell K; Arslanian S
J Clin Endocrinol Metab; 2011 May; 96(5):1311-9. PubMed ID: 21325466
[TBL] [Abstract][Full Text] [Related]
25. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
26. The effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ovarian ultrasonographic markers, body fat mass index, leptin, and ghrelin.
Cakiroglu Y; Vural B; Isgoren S
Arch Gynecol Obstet; 2013 Jul; 288(1):213-20. PubMed ID: 23377194
[TBL] [Abstract][Full Text] [Related]
27. Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome.
Cinar N; Harmanci A; Bayraktar M; Yildiz BO
Clin Endocrinol (Oxf); 2013 Mar; 78(3):379-84. PubMed ID: 22509734
[TBL] [Abstract][Full Text] [Related]
28. Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin.
Ibáñez L; López-Bermejo A; Díaz M; Enríquez G; Valls C; de Zegher F
Clin Endocrinol (Oxf); 2008 Feb; 68(2):317-20. PubMed ID: 18031315
[TBL] [Abstract][Full Text] [Related]
29. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Gambineri A; Pelusi C; Genghini S; Morselli-Labate AM; Cacciari M; Pagotto U; Pasquali R
Clin Endocrinol (Oxf); 2004 Feb; 60(2):241-9. PubMed ID: 14725687
[TBL] [Abstract][Full Text] [Related]
30. Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.
Lázaro I; Díaz M; Cabré A; Masana L; Ibáñez L
Gynecol Endocrinol; 2011 Nov; 27(11):935-9. PubMed ID: 21605000
[TBL] [Abstract][Full Text] [Related]
31. Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months.
Ibáñez L; López-Bermejo A; Díaz M; Enríquez G; del Río L; de Zegher F
Clin Endocrinol (Oxf); 2009 Sep; 71(3):351-7. PubMed ID: 19018783
[TBL] [Abstract][Full Text] [Related]
32. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
[TBL] [Abstract][Full Text] [Related]
33. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
34. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
[TBL] [Abstract][Full Text] [Related]
35. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
36. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome.
Kaya MG; Calapkorur B; Karaca Z; Yildirim S; Celik A; Akpek M; Unluhizarci K; Kelestimur F
Clin Endocrinol (Oxf); 2012 Dec; 77(6):885-92. PubMed ID: 22563947
[TBL] [Abstract][Full Text] [Related]
37. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide.
Ibáñez L; Potau N; Marcos MV; de Zegher F
J Clin Endocrinol Metab; 2000 Sep; 85(9):3251-5. PubMed ID: 10999817
[TBL] [Abstract][Full Text] [Related]
38. Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Ibáñez L; Del Río L; Díaz M; Sebastiani G; Pozo ÓJ; López-Bermejo A; de Zegher F
J Adolesc Health; 2017 Oct; 61(4):446-453. PubMed ID: 28712591
[TBL] [Abstract][Full Text] [Related]
39. Which treatment options should be used in adolescents with polycystic ovary syndrome?
Villa P; Di Sebastiano F; Rossodivita A; Sagnella F; Barini A; Fulghesu AM; Lanzone A
J Pediatr Endocrinol Metab; 2004 May; 17(5):705-10. PubMed ID: 15237703
[TBL] [Abstract][Full Text] [Related]
40. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
Ibáñez L; Valls C; Potau N; Marcos MV; de Zegher F
J Clin Endocrinol Metab; 2000 Oct; 85(10):3526-30. PubMed ID: 11061495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
